Because there is more to do
Opening the conversation:
How can pharma companies better respond to the health and wellbeing needs of patients?
We conducted surveys with the public, patients, carers, patient advocates and healthcare professionals across eight European
countries, to better understand what more we can do. This report is a synthesis of those findings.

We are listening

We have heard you

Let’s act together!

What more can we do?
Bristol Myers Squibb’s mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious disease. But we firmly believe that this does not stop with
our science and innovative medicines.
As a responsible corporate citizen, we should always strive to do more to support patientsalong their treatment journeys, and work in partnership across healthcare to enable this.
It is this belief that led to the creation of the initiative ‘Because there is more to do’.
We wanted to understand:• What healthcare challenges and unmet needs do people and their loved ones have?
• What do you think can be done to improve peoples’ lives and make a bigger contribution?
• How can pharma companies better address them?
• What is your opinion of pharma companies and their role in society?

It all starts with listening:

Our journey started in late 2020 as we reflected on these important questions. This led us to ask whatmore can we do as a leading biopharmaceutical company and member of society? We decided that
we cannot determine this alone. To best understand what is needed, we conducted surveys across eight
European countries to listen to your views.

The ‘Because There is More To Do’ surveys:••

A public survey* open to everyone.
A patient & professional survey** This ‘deeper-dive’ study engaged patients, caregivers, patient advocacy
groups and healthcare professionals to gain a better understanding of unmet needs and challenges thatpeople face, asking for their suggestions on how pharma companies can solve them.

Respondents contributed from Austria, Belgium, The Netherlands, Denmark, Finland, Norway, Sweden and Switzerland.

The ‘Because There is More To Do’ surveys:* The public survey was an open invitation from Bristol Myers Squibb
asking people to share their views and opinions on the pharmaceuticalindustry and companies, and the challenges people face for healthcare
provision. 821 adults responded to an online public survey across eight
countries via social media, paid ads on healthcare sites and direct mails
from BMS. Respondents were predominantly patients, healthcare &pharma professionals.
** The patient & professional survey was done across eight countries. It
was based on two anonymous online surveys: one with feedback from839 primary care physicians, cardiologists and oncologists; another withresponses from 214 oncology or atrial fibrillation patients, and caregivers ofpatients with these conditions. In addition, exploratory qualitative research
was done with 40 patient advocacy groups to gain greater insights.
All surveys were done in Austria, Belgium, Denmark, Finland, The
Netherlands, Norway, Switzerland and Sweden.
For full details on the public and patient & professional surveys please see
the Annex.

First of all: Thank you
To the people, patients, carers and healthcare professionals acrosseight European countries.

For taking the time to shareyour feedback, thoughts and insight to our surveys, on how you
think the pharma industry can provide support, beyond medicines,
and what more you think we can do.

For your transparency and honesty.

This has given us a clear idea of the the unmet needs of patientsand their relatives and what more is expected from pharma.

This gives us a mirror to look at ourselves in a different light.

From the outside in. To see how we can do more to make a positive
contribution to:• The lives of patients and their loved ones
• Supporting patient advocacy groups and healthcare professionals• Society at large

We are listening:Your insights will inspire new approaches
We commit to sharing and discussing these findings with stakeholders incountries where Bristol Myers Squibb serves.
Your insights will inspire us to explore new ideas together for local
community initiatives. We will ensure that we communicate to you
more on these developments - through our website and social media.

Synthesis report

Public survey

What you told us

Synthesis report

Deep-dive:professional
and patient
surveyWhat are thecurrent unmet needs?
How can pharma partner tohelp support patients andmeet these challenges?

Symptom awareness

Early signs detection,
supporting disease
prevention andeducational activities

Diagnosis

Treatment plan

Improving patients’
understanding of
their condition

Involving patientsin the Tx decisionmaking process

Aiding physiciansin determining theirdiagnosis

Ensuring access toinnovative treatments

Follow-up

Help patients manage
treatment side effects

Present day

Helping patients adapt
to living with an illness
Coping with thefinancial burden of
the condition

Helping patients deal with emotional impacts of the condition on them and their family
Increasing the time physicians spend with their patients
Disease screening / prevention programmes
Disease education
Online or F2F interactions between health care professionals & patients
Physician capacity & efficiency
Supporting patients to cope with the financial burden of illness
Emotional support

Online or F2F interaction between patients

Public survey insights

What you told us

What you told us:
We can improve impact by better communicating & collaborating with others
People responding to the public survey* are callingfor pharma companies to:Show responsible behaviour in all aspects of business.
Be a responsible corporate citizen.
Support patients beyond treatments.
We agree. Pharma should play a wider role inhealthcare & society. We are active in all theseareas today, and will respond to your insights, tosee what more we can do.

*Public survey open to every one in The Netherlands, Denmark, Finland, Norway, Sweden and Switzerland, 821 adults responded:predominantly patients and carers, healthcare & pharma professionals.

What the public told us

Pharma’s primary role is toprovide innovative
medicines to patients

77%
86%

of survey respondents agree.
agree that pharma companies do valuable
research to develop new medicines.

What the public told us

Pharma companies
have a responsibility to

improve patients’
overall quality of life

91%

of survey respondents agree that pharmacompanies should improve patients’quality of life.

55%

agree or strongly agree that BMS
creates new medicines which improve
patients’ quality of life.

What the public told us

Pharma should bea responsible
corporate citizen

90%
49%

of survey respondents agree.
say pharmaceutical companies
are doing this.

Clearly, there ismore to be done here.

What the public told us

Pharma in society: contrasting views

value, money & responsibility

50%
53%

of survey respondents agree or strongly agree thatpharma is only interested in making money.
agree that pharma companies care about thepatients for whom they produce medicines.

What respondents expect of us

Clarity on the value of medicines
Some comment that they do not understand pricing, value and the cost of medicines.
We will communicate more on thisto help improve understanding.

A need for greater transparency
Many respondents say they do not know pharma companies or understand what they do.
We commit tocommunicating more clearly.
A number of responses received to open-ended questions.

What the public told us

Pharma should playa wider role inhealthcare & society

55%

of respondents say that pharma needs
to collaborate more with healthcare
professionals, the medical communityand patient organisations.
We appreciate this useful perspective:
as a next step we will engage with thesegroups to determine what more we can do.

What the public told us

Be more involved in

education & information

52%of respondents agree that pharma companies provide
educational support to patients & their families.

What respondents expect of us
More support for disease-specific information,for example: web & post-treatment services.

46%

say pharma can better support
education for disease prevention.

Of 11% of potential services assessed: 41% specified education; 42% screening, 46% better
education for disease prevention.

What the public told us

What more can we do?
We asked survey respondents:
How can pharma companies bettersupport patients and local communities:
what are your ideas for projects andactivities?*
Here are people’s Top-5 suggestions:(The word cloud shows the strongest feelings across all respondents.
Hover your mouse over key words to discover the suggestions.)* Word cloud summary of responses to the question: which projects/activities could pharmaceutical companies conduct to support patients or local communities? (open-ended positive)

Deep-dive survey insights

Patient & professional perspectives

Patient & professional perspectives
What more can we do to support patients along their treatment journeys,
and be a partner across the healthcare landscape to enable this?
The patient & professional survey* was a deeper-dive to hear the views of patients andhealthcare professionals. They offered feedback about current unmet needs, peoples’ viewsof pharma, and potential areas where Bristol Myers Squibb and pharma can take action.
To do this we asked for feedback from*:• Patients in oncology and atrial fibrillation and their carers.
• Patient advocacy groups working in these disease areas.
• Primary care physicians, oncologists and cardiologists.

Some highlights:
Unmet needs, for example: Prevention & diagnosis; coping with mental
stress; better disease education; a need for more doctor-patient time.
Perceptions of pharma: Many are well-informed of pharma companies’
activities, and feel pharma can play a wider role – beyond medicines.
New areas where pharma can act, for example: Emotional support& education; financial support; new partnerships with patients, caregivers,
professionals; facilitating face-to-face and peer groups interactions.

Thank you for these valuable insights.
They inform what more we can do and theactions we can take together, going forward.

*Online study with 214 oncology or atrial fibrillation patients and caregivers of patients with those conditions in Austria, Belgium, The Netherlands, Denmark, Finland, Norway, Sweden and
Switzerland; all countries weighted equally. Exploratory qualitative research was also done with 40 patient advocacy groups. For full details, please see the Annex

Identifying key needs along the patient journey

Unmet needs

Across the patient journey there are a broad range of needs, dependent on individuals’ exact circumstances and conditions.
However patients, patient association groups and physicians most commonly identify the following areas as key needs
across the patient journey.

Symptom awareness

Early signs detection,
supporting disease
prevention andeducational activities

Diagnosis

Treatment plan

Improving patients’
understanding of
their condition

Involving patientsin the Tx decisionmaking process

Aiding physiciansin determining theirdiagnosis

Ensuring access toinnovative treatments

Helping patients deal with emotional impacts of the condition on them and their family
Increasing the time physicians spend with their patients

Follow-up

Present day

Helping patients adapt
to living with an illness
Help patients manage
treatment side effects
Coping with the financial
burden oft he conditionSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Disease prevention

Pharma can bring valuable support with education actions

HCPs

of the health care professionals surveyed, who
say that pharma should invest in local activities*,25%

say they would most like to see pharma
invest in ‘supporting education

initiatives for disease prevention’.
Selected from a list of 10 points.

Insights from patient groups

PAGs

There is a need for more knowledge Here, a key objective is to raise disease awareness among the public to enable better management at the earlystages of an illness. But patient association groups still struggle to spread awareness to a wider audience.
on diseases & treatment options.

*Those who tend to agree or strongly agree that pharmaceutical companies should support activities in partnership with patient groups, or other pharmaceutical companies, or aim to support patients beyond medicinal treatment.
B4. You indicated that pharma companies should invest in meaningful local activities, please select which of the following, you would like to see investment into the most Base: n=831 Those HCPs who selected that pharmacompanies should support activities with patient groups/other pharma companies/support beyond medicinal treatment

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Reaching a correct diagnosis
Physicians say this is a key challenge

HCPs

38%

of physicians surveyed say that

‘determining the diagnosis’is among the Top-5 most challenging
stages for managing patients.
Selected from a list of 28 points.

Insights from patient groups

PAGs

Reaching a correct diagnosis can be difficult.

“Heart disease is often a silent disease, it can be silent for many years”“Often, the symptoms aren’t being connected to the right disease.”
Switzerland

QA1. Select item importance (pick max. 5 items out of 28) - Which of the following stages would you say present the most challenges to you as a physician? Base: Total n= 839 Physicians

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Better disease education is needed
Say patients, caregivers & physicians

HCPs

23%

of physicians surveyed say that ‘educating thepatient about their condition’ is among theTop-5 most challenging stages for managing patients.
Selected from a list of 28 points.

Patients
Caregivers

25%of patients and caregivers say that

‘understanding the condition’ is among theirTop-5 most challenging stages of their condition.
Selected from a list of 23 points.

Insights from patient groups

PAGs

Empowered patients.

Some patient association groups acknowledge the difficulties that patients have to understand their disease.
These groups aim to raise knowledge, awareness and educate patients. Some groups say they want patients to be
more empowered and involved in their treatment decisions.

QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base: Patients / caregivers (n=214)
QA1. Select item importance (pick max. 5 items out of 28) - Which of the following stages would you say present the most challenges to you as a physician? Base: Total n= 839 Physicians

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Discussions on treatment options

Patients, caregivers & physicians agree this needs improving

HCPs

23%

of physicians surveyed say that ‘discussing treatment
options with the patient’ is among the Top-5 mostchallenging stages for managing patients.
Selected from a list of 28 points.

Patients
Caregivers

14%of patients and caregivers say that ‘discussing
treatment options’ is among the Top-5 areas
where they would value more support.
Selected from a list of 23 points.

Insights from patient groups

PAGs

Some patient groups say that patients, their friends and families often ask them about current
and future ‘treatment options’, and sometimes feel ill-equipped to educate them.

QA5. Statement ranking (23 statements) - which of the following stages, would you/the person you care for have appreciated more support? Base: Patients / caregivers (n=214)
QA4. Select item importance (pick max. 5 items out of 28) - At which of the following stages would you like to be able to provide more support to your patients? Base: Total n= 839 Physicians

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Access to innovative medicines
Some physicians want to provide more support

HCPs

26%

of physicians surveyed say that they wantto provide more support to their patientsto ‘access innovative medicines’.
Selected from a list of 28 points.

Patients
Caregivers

11%of patients and caregivers say that‘access to innovative medicines’
is among the Top-5 most challenging
stages of their condition.
Selected from a list of 23 points.

A4. At which of the following stages, if any, would you like to be able to provide more support to your patients beyond the provision of medicines and surgery, but are unable to do so currently? [select up to five from a list of 28]
Base: n=839 (All physicians) QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base patients/caregivers n=214)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Managing the side effects of treatment
A challenge for patients & physicians

Patients
Caregivers

25%of patients and caregivers surveyed say that‘treatment of side effects’ is among theTop-5 most challenging stages of their condition.
Selected from a list of 28 points.

HCPs

24%

of physicians say that ‘managing treatment
side effects’ is among the Top-5 mostchallenging stages for managing patients.
Selected from a list of 23 points.

Insights from patient groups

PAGs

Getting the right treatment and coping with its
side effects can be a challenge for patients.

There are two main challenges:• Getting the right therapy for patients.
• But mostly, it is handling the side effects.

QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base: Patients / caregivers (n=214)
QA1. Select item importance (pick max. 5 items out of 28) - Which of the following stages would you say present the most challenges to you as a physician? Base: Total n= 839 Physicians

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Dealing with financial impacts of illness
A ‘key challenge’ for patients & caregivers

Patients
Caregivers

22%
19%

of patients and caregivers surveyed say that‘dealing with the financial burdencaused by having an illness’ is among theTop-5 most challenging stages of their condition.
Selected from a list of 23 points.

of patients and caregivers say that ‘dealing

with the financial burden caused byan illness’ is among the Top-5 areas where
they would appreciate more support.

Selected from a list of 28 points.

Insights from patient groups“There are a lot of patients that need psychological support, others need financial support.”
PAGs

A Swiss patient association group

QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base: Patients / caregivers (n=214)
QA5. Statement ranking (23 statements) - which of the following stages, would you/the person you care for have appreciated more support? Base: Patients / caregivers (n=214)

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Helping patients live with their condition
More can be done, say patients, caregivers & physicians

Patients
Caregivers

Of patients and caregivers who shared the Top-5
most challenging stages of their condition,

13%
28%

say that ‘managing the physicalOf doctors who shared their Top-5 mostchallenging stages for managing patients,
HCPs

impact of the condition on
the family’ is a challenge.
Selected from a list of 23 points.

Citing their Top-5 stages where more support would bevalued, beyond the provision of medicines and surgery,say that ‘learning to adapt to livewith the condition’ is a challenge.
Selected from a list of 23 points.

13%

Insights from patient groups

PAGs

26%

say ‘helping patients to adapt
to living with the condition’.
Selected from a list of 28 points.

Some patient association groups surveyed currently
offer a range of practical and emotional support.

say ‘helping patients cope with thephysical impact caused by the condition’.
Selected from a list of 28 points.

“The psychologist at the hospital… I always try toadvise people who are having a hard time to use that.”
Belgium

A1. Thinking about your experience of treating and managing your pts, which of the following stages would you say present the most challenges to you as a physician? [select up to 5 from a list of 28] Base: n=839 (All physicians) A4. At which of
the following stages, if any, would you like to be able to provide more support to your patients beyond the provision of medicines and surgery, but are unable to do so currently? [select up to 5 from a list of 28] Base: n=839 (All physicians)
A5. At which of the following stages, if any, do you think [PN: PATIENT INSERT you] [PN: CARER INSERT the person you care for] would have appreciated more support? [select up to 5 from a list of 23] Base=214 All patients / caregivers

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

Coping with the mental stress of a conditionA ‘key challenge’, say patients, caregivers & physicians

HCPs

28%

of physicians surveyed say that ’helping patientscope with the mental stress caused by thecondition’ is among the Top-5 stages where theywould like to provide more support to patients.

Selected from a list of 28 points.

Patients
Caregivers

30%of patients and caregivers say that ‘coping withmental stress caused by the condition’ isamong their Top-5 most challenging stages for themor person they care for.
Selected from a list of 23 points.

Insights from patient groups

PAGs

Patient groups say that the physical burden of the condition has a heavy effect on patients’ psychological and emotional wellbeing, to theextent patients are often unable to go to their immediate support network of family and friends, so peer support is vital.

QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base: Patients / caregivers (n=214)
QA4. Select item importance (pick max. 5 items out of 28) - At which of the following stages would you like to be able to provide more support to your patients? Base: Total n= 839 Physicians

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Unmet needs

A need for more doctor-patient timeA ‘most common challenge’ reported by physicians

HCPs

41%

of physicians surveyed say that ‘having sufficient

time to provide adequate care to all thepatients I have to manage’ is among the Top-5
most challenging stages for managing patients.

Selected from a list of 28 points.

Patients
Caregivers

24%of patients and caregivers say that having ‘moretime in medical consultations’ is among theTop-5 services where they would like more access.
Selected from a list of 19 points.

Insights from patient groups

PAGs

Critical challenges to tackle.

Patients want to feel heard by health care professionals, and need outlets to discuss theiremotional response - following often stressful and short consultations.

QA1. Select item importance (pick max. 5 items out of 28) - Which of the following stages would you say present the most challenges to you as a physician? Base: Total n= 839 Physicians
A8. Which of the following services, if any, would you / the person you care for like access to? Base: Total patients/caregivers n=214

Qualitative researchViews & perceptions of pharma

Toward new roles for pharma

How can we best take action to support patients’ unmet needs?
Reflecting on the unmet needs voiced by patients and professionals in this survey, the rich and informative feedback that was shared reveals new areas where respondents
think pharma can do more. The following two sections present these groups’ current views of pharma and their suggestions for how pharma can support in new ways.

How well do survey respondents know pharma companies?

58%• Healthcare professionals say they are adequately or well-informed.

• Most patients say they have limited knowledge of companies and their activities.

35%
40%
26%

Patients

1%
1%

2%
1%

5%
1%

Don't know

Prefer not to say

No knowledge at all

HCPs

B1/B1. Overall, how would you rate your knowledge of pharmaceutical companies? Base: Total patients/caregivers n=214, physicians n=839

17%
13%

Not very much knowledge

A fair amount ofknowledge

A great deal of knowledge

Views & perceptions of pharma

Very few physicians currently see pharma
as a partner for providing patient care

HCPs

6%

of health care professionals surveyed saythat pharma is currently important inonlyonluy

Onlyproviding overall care to patients.

But they do see hospital nurses (59%),
other physicians (56%), and community
nurses (34%), as the most important partners.
Selected from a list of 14 points.

A6. Which stakeholders, if any are important in supporting/partnering with you when it comes to providing overall patient care? [Select up to three responses from a list of 14] Base: n=839 physicians

Views & perceptions of pharma

But others think pharma can play a wider role:
beyond providing medicines
Voices from a majority of patients, caregivers & health care professionals
Deliver innovative medicines
Be responsible corporate
citizens in my country
Improve patients’ quality of life
Ensure that all patients get rapid accessto new medicines and therapies
Actively contribute to a costeffective healthcare system

94%
88%
86%
85%
85%

HCPs

Patients
Caregivers

Expectations ofpharmaceuticalcompanies

82%
81%
80%
79%
78%

Ensure that all patients get rapid
access to new medicines and therapies
Support activities in partnershipwith healthcare professionals
Improve patients’ quality of life
Be responsible corporate citizens
in my country
Deliver innovative medicines

Percentage of respondents who agree or strongly agree on a 5-point scale with each statement.

B3/B4. To what extent do you agree or disagree that pharmaceutical companies should do the following? [1=Strongly disagree, 2=Tend to disagree, 3=Neither agree nor disagree, 4=Tend to agree, 5=Strongly agree,
Don’t know, Prefer not to say (Total patients/caregivers n= 214, physicians n=839).

How pharma can support

How can BMS support patients, carers and physicians?

Patients, carers, patient association groups and physicians identified solutions that can improve patient experiences along their journey.

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Disease screening / prevention programmes

Including disease prevention education initiatives and screening programs

Disease education

Access to info and support in understanding the condition, treatment options and their side effects

Online or F2F interactions between health care professionals & patients
Potentially also helping to support both emotional and educational needs of patients

Physician capacity & efficiency

Potentially collaborating with the medical community to develop tools orservices to increase efficiencies

Online or F2F interaction between patients

Supporting patients to cope with the financial burden of illness

Emotional support
Formalize emotional support programmes for patients, caregivers and their families

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

How pharma can support

A call for more disease prevention & screening
Patients say pharma can provide better support

HCPs

Patients
Caregivers

21%
23%
23%

of physicians surveyed say that ‘disease prevention programs’
are among the Top-5 services that wil improve patients’ experience ofliving with their condition.
Selected from a list of 19 points.

of patients and caregivers say that ‘disease screening’ is among
the Top-5 services that they want to see better supported by pharma.
Selected from a list of 28 points.

of patients and caregivers say that ‘disease prevention programs’ areamong the Top-5 services that pharma can better support.
Selected from a list of 13 points.

Insights from patient groups

PAGs

Some groups cite lobbying as a key objective.
Others focus on prevention and early detection of the specific cancer that they address.

QC2. Select item importance (pick max. 5 items out of 13) – Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients / caregivers (n=214)
QA7. Select item importance (pick max. 5 items from 19) - Which, if any, of the following services would improve patients’ experiences living with their conditions? Base: Physicians (n=839)

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

How pharma can support

Potential to build physicians' capacity; create new tools & services
Benefits of medical community & health-tech partnerships

HCPs

Patients
Caregivers

22%
38%
54%

of physicians surveyed say that ‘insufficient physician
time and capacity’ is an unmet need they think can beaddressed together with pharma companies.
Selected from a list of 12 points.

of patients and caregivers say that ‘health technology
companies’ are among the Top-5 groups with whom they
think pharma companies can collaborate more.
Selected from a list of 12 points.

of patients and caregivers say that ‘health care professionals
and the medical community’ are among the Top-5 groups
with whom they think pharma companies can collaborate more.
Selected from a list of 12 points.

Insights from patient groups

PAGs

Pharma can support hospitals by helping
patients along their treatment journeys.

Some patient groups commented that pharma can help with psychological support,
training and services, for example by launching rehabilitation centres and helping
with skilling of health care professionals.

C3. Which, if any, of the following people or groups do you think pharmaceutical companies should be cooperating with more? (pick max. 5 items from 12) – People or groups patients and caregivers think pharma should be cooperating withmore Base: Patients / caregivers (n=214) A9. Beyond medication, which if any, of these unmet needs do you think could be addressed in collaboration with the pharmaceutical industry to support your patients? Base: Physicians who think
there are needs that can be addressed by pharma (n=792)

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

How pharma can support

Direct financial support from pharma
Requested by some patients

HCPs

Patients
Caregivers

25%
10%
20%

of physicians surveyed say that ‘direct access to practicalsupport’is among the Top-5 services that will improve patients’experience of living with their condition.
Selected from a list of 19 points.

say that ‘direct access to financial support plans’
are among the Top-5 services that will improve patients’experience of living with their condition.
Selected from a list of 19 points.

of patients and caregivers say that ‘direct access to financial
support plans’ is among the Top-5 services they would like to access.
Selected from a list of 13 points.

Insights from patient groups

PAGs

While not all patient association groups interviewed can provide financial support to patients, some say they want to set up funds to help patientsduring tough times. They commented that support from pharma is mainly financial. Some groups say this tends to be limited to financing events andinformation materials for events, such as flyers.
Qualitative research

A8. Which of the following services would you/the person you care for like access to? (pick max. 5 items out of 19) Base: Patients / caregivers (n=214)
QA7. Select item importance (pick max. 5 items from 19) - Which, if any, of the following services would improve patients’ experiences living with their conditions? Base: Physicians (n=839)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

How pharma can support

Emotional support for patients, carers & their families
Pharma facilitation would be useful

HCPs

Patients
Caregivers

28%
31%
31%

of physicians surveyed say that ‘helping patients cope withmental stress caused by the condition’ is among the Top-5
areas where they would like toprovide more support to their patients.
Selected from a list of 28 points.

of patients and caregivers say that ‘emotional support for patients’ isamong the Top-5 services they would like to see better supported by pharma.
Selected from a list of 13 points.

of patients and caregivers say that ‘post-treatment services’ areamong the Top-5 services they would like to see better supported by pharma.
Selected from a list of 13 points.

Insights from patient groups

PAGs

Some groups agree that emotional support is key and a partiallyunmet need for many people. But is this an area where pharma
should be directly involved?

“I don't know what role a pharmaceutical company can play.
The emotional support comes more from the other peers; I don't thinka pharmaceutical company can contribute anything to that.”
Belgium

QA4. Select item importance (pick max. 5 items out of 28) - At which of the following stages, if any, would you like to be able to provide more support to your patients beyond the provision of medicines and surgery, but are unable to do socurrently? Base: Total n= 839 Physicians QC2. Select item importance (pick max. 5 items out of 13) – Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients / caregivers (n=214)

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

How pharma can support

Patient education is an area where pharma can support
All stakeholders agree

HCPs

Patients
Caregivers

19%of physicians surveyed say that ‘insufficient disease
information for patients’ is an unmet need they thinkcan be addressed together with the pharma industry.

14%of patients and caregivers say that ‘disease education’is among the Top-5 services they would like to see bettersupported by pharma.

Selected from a list of 12 points.

Selected from a list of 13 points.

Insights from patient groups

PAGs

In addition to disease awareness and early-signs detection, patient groups also stressed the need to educate patients on the treatment options
available to them. The groups responding feel that education is a clear opportunity for greater collaboration with pharma. Here, pharma can provide
information on side effects of existing medications’ and expectations for emerging new treatments.
Qualitative research

A9. Beyond medication, which if any, of these unmet needs do you think could be addressed in collaboration with the pharmaceutical industry to support your patients? Base: Physicians who think there are needs that can be addressed bypharma (n=792) A8. Which of the following services would you/the person you care for like access to? (pick max. 5 items out of 19) Base: Patients / caregivers (n=214)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

How pharma can support

Pharma can support platforms for patient-physician interactions
Patients, carers and physicians see opportunities for face-to-face and online line approaches
Face-to-facePatients
Caregivers

22%

Face-to-faceof patients and caregivers surveyed saythat ‘face-to-face support groups
HCPs
with physicians’ are among the Top5 services they would like to see bettersupported by pharma.
Selected from a list of 13 points.

Online support

23%

of patients and caregivers say that‘online support groups withphysicians’ are among the Top-5

services they would like to see bettersupported by pharma.

27%

Selected from a list of 19 points.

Online support

12%

PAGs

Groups flagged the prospect of online sessions with health care
professionals and expert panels as popular. These sessions areappreciated as they enhance collaboration among stakeholders.

of physicians say that ‘online support
groups with physicians’ are among theTop-5 services that will improve patients’experience of living with their condition.
Selected from a list of 19 points.

Selected from a list of 18 points.
Insights from patient groupsof physicians say that ‘face-to-face support
groups with physicians’ are among the Top-5
services that they think will improve patients’experience of living with their condition.

“Well, I think we also need to involve pharmaceutical companies and treat the patient from a holistic care
perspective; and the doctor doesn't have the time to do it. Another difficulty is that doctors are not trained tocollaborate. I think we really need to foster a spirit of collaboration, which the industry can help with.”
Switzerland

QA7. Select item importance (pick max. 5 items from 19) - Which, if any, of the following services would improve patients’ experiences living with their conditions? Base: Physicians (n=839)
QC2. Select item importance (pick max. 5 items out of 13) – Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients / caregivers (n=214)

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

How pharma can support

Online & face-to-face peer groups
Patients and caregivers call for better support
Face-to-facePatients
Caregivers

24%of patients and caregivers surveyed say that ‘face-to-face support
groups with other patients with the same condition’ are among
the Top-5 services they would like to see better supported by pharma.
Selected from a list of 13 points.

Online support

23%

say that ‘online support groups with other patients withthe same condition’ are among the Top-5 services they would
like to see better supported by pharma.
Selected from a list of 13 points.

Insights from patient groups

PAGs

Online forums that encourage contact between patients and peer support networks givethem reassurance that they are not alone and many others like them are coping. Patient
support networks such as family and friends can also benefit from forums.

“They are looking for information, exchange with people with the samedisease. Usually, the second or third time they come to tell their own story
and the others tell them about their experiences.”
Austria

QC2. Select item importance (pick max. 5 items out of 13) – Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients / caregivers (n=214)

Qualitative researchReflections & conclusions

Our commitment to next steps

Feedback from Patient Association Groups: Key findings

Reflections & conclusions

Groups would welcome support from pharma; but their thinking is often limited to financial
interactions, though there is certainly scope to partner

Education

Collaboration

Facilitation

Funding

Groups see a need to help raiseawareness and provide increased
knowledge on diseases, and on available
and new treatments. Some want toincrease their knowledge, support
patients for disease-specific andtreatment-related questions.

Some groups welcome greatercollaboration with pharmacompanies, for example for
information sharing and education.

Groups say that emotional support
to patients and their loved ones is a
top priority.

Some groups suggest that a fundcould help patients accesstreatment, provide money if they
are unable to work, or help withtravel costs to treatment.

Suggestion from patient groups:
Pharma can help by advocating for
better quality education, and testing forearlier diagnosis of some cancers.

Most see pharma as side-line
supporter, rather than in visible ‘onthe-pitch’ activities directly withpatients.

Here, more can be done to support
and connect peers, optimise existing
resources.
Suggestion from patient groups:
Pharma can facilitate - supporting
patients with forums and providing
resources for peer support meetings.

Suggestion from patient groups:
Pharma can launch rehabilitation
centres; help with skilling andcapacity building for health care
professionals; or provide funding
for psychological support staff
that’s accessible to patients.

Our starting point for new partnerships
We have heard you, and commit to taking action together with you

What we have heard from you

Is there a role for BMS & pharma?

The feedback that you have shared in the
public and patient & professional surveys isenlightening. We appreciate your candid input.

We wanted to understand if there is a role for
BMS and pharma beyond delivering innovative
medicines. And if so, what is it?

With the initiative ‘Because there is more to do’
we embarked on a journey to learn more about
your situations, your concerns, what you expect
of us, and where you think pharma can domore to support patients and society.

Your responses tell us that .pharma has a role toplay.

Our journey together starts today
We will now build on what we have learned fromyou. The next step is deeper engagement, toexplore where we can most effectively support
your needs.
In the coming months we will open a wider
dialogue with the healthcare industry.

Our commitment:
what you can expect from BMS
The conclusion of this report is the beginning of
our future journey together. We commit toworking with you to take action in areas you
have defined, including: new partnerships withpatient organisations and health care
professionals.

Reflections & conclusions

Technical notesTechnical notes
Technical Note – Patient and Caregiver Survey
On behalf of Bristol Myers Squibb, Ipsos MORI carried out an online
survey with a sample of 214 patients and caregivers (oncology
patients, oncology caregivers, atrial fibrillation patients, atrial
fibrillation caregivers) across eight European countries (Austria,
Belgium, Denmark, Finland, Netherlands, Norway, Sweden,
Switzerland). Online surveys were conducted between 11th
January 2021 and 26th April 2021.
Respondents were recruited via online panels, and as such, thesample contains respondents who are engaged with market
research panels and chose to take part in the survey.
The sample includes the following per country:
AT

BE

DK

FI

NL

NO

SE

CH

Total

30

30

20

30

30

15

29

30

Oncology
patients

8

8

8

8

8

10

8

8

Oncology
caregivers

7

7

7

7

7

5

7

7

Atrialfibrillation
patients

8

Atrialfibrillation
caregivers

7

8

7

3

2

8

7

8

7

0

0

8

6

8

7

Technical Note – Health Care Professional Survey
On behalf of Bristol Myers Squibb, Ipsos MORI carried out an
online survey with a sample of 839 health care professionals(primary care physicians, cardiologists andoncologists/haematologists) across eight European countries(Austria, Belgium, Denmark, Finland, Netherlands, Norway,
Sweden, Switzerland). Online surveys were conducted between
11th January 2021 and 26th April 2021.
Respondents were recruited via online panels, and as such, thesample contains respondents who are engaged with market
research panels and chose to take part in the survey.
The sample includes the following per country:
AT

BE

DK

FI

NL

NO

SE

CH

Total

105

120

100

93

120

70

116

115

PCPs

50

50

50

51

50

42

50

50

Cardiologists

30

40

30

22

40

18

40

40

Oncologists/haematolog
ists

25

30

20

20

30

10

26

25

Technical Note - Patient Advisory Group Qualitative Research:
On behalf of Bristol Myers Squibb, Ipsos MORI conducted
exploratory qualitative research in eight European markets(Austria, Belgium, Denmark, Finland, Netherlands, Norway,
Sweden, Switzerland). In total, 40 respondents completed a webassisted telephone in-depth interview (37 respondents were
working for an oncology patient advisory group, 3 for an atrial
fibrillation patient advisory group). Respondents were recruited
via telephone through third party panel providers. Interviews
were carried out between 11th January 2021 and 26th April 2021.
Please note that this qualitative research approach explores therange of attitudes and opinions of participants in detail and thatthe findings are descriptive and illustrative, not statistically
representative.

Technical Note – Single-blinded Open Invitation Digital ‘Humanity’
Survey:On behalf of Bristol Myers Squibb, Ipsos MORI carried out an online survey
with a sample of 821 adults aged 16 and over, across nine European
countries (Austria, Belgium, Denmark, Finland, Luxembourg,
Netherlands, Norway, Sweden, Switzerland). Interviews were conducted
between 20th November 2020 and 18th January 2021.
Respondents were invited to respond to an open invitation from Bristol
Myers Squib to share their views and suggestions on their opinions of thepharmaceutical industry, pharmaceuticals companies and the challenges
they face regarding healthcare provision in their country. This invitation
was shared in a range of paid advertising channels on websites and social
media, but also direct emails and organic posts:•
paid post on LinkedIn;•
organic posts on LinkedIn;•
direct email to BMS employees;•
hosting on Bristol Myers Squibb websites.
As such, the sample includes a mix of respondents who responded to theonline campaign and chose to take part and is not a representative
sample of the population of the countries included in the campaign. It isalso likely respondents are already engaged with Bristol Myers Squib
and/or the pharmaceutical industry in general. The sample includes
members of the public, patients, caregivers, health care professionals,
pharmaceutical industry employees and their friends and family. Results
are indicative in nature and reflect the responses of the survey
participants only. Participants outside of the countries listed werescreened out and could not participate.
In total there were 129,688 clicks onto the survey, with 821 respondents
completing the survey.
The sample includes the following per country:
AT

BE

DK

FI

LU

NL

NO

SE

CH

Total

82

325

33

30

0

193

35

55

68

Health care
professionals

20

60

14

11

0

19

9

10

16

Patients or
caregivers

16

105

8

6

0

79

11

13

19

Pharmacompany
employees

22

96

4

8

0

39

7

7

24

Other

34

119

13

14

0

79

12
33
23
Qualitative research

When reporting on global results, all participants are included and noweighting has been applied to the data

Because there is more to do

We are listening

We have heard you

Let’s act together!